NASDAQ:JNCE

Jounce Therapeutics - JNCE Stock Forecast, Price & News

$2.20

-0.10 (-4.35%)

(As of 09/29/2022 12:00 AM ET)

Add

Compare

Today's Range: $2.12
▼
$2.32
50-Day Range: $2.20
▼
$4.92
52-Week Range: $2.12
▼
$9.81

Volume: 155,022 shs
Average Volume: 324,918 shs
Market Capitalization: $113.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Jounce Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 400.0% Upside
$11.00 Price Target
Short Interest: Bearish
5.85% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.67
Upright™ Environmental Score
News Sentiment: 1.41
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.29) to ($2.32) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

312th out of 1,097 stocks

Biological Products, Except Diagnostic Industry

47th out of 172 stocks

3.5

Analyst's Opinion

Consensus Rating
Jounce Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, Jounce Therapeutics has a forecasted upside of 400.0% from its current price of $2.20.
Amount of Analyst Coverage
Jounce Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.85% of the float of Jounce Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Jounce Therapeutics has a short interest ratio ("days to cover") of 7.6.
Change versus previous month
Short interest in Jounce Therapeutics has recently decreased by 3.41%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Jounce Therapeutics does not currently pay a dividend.
Dividend Growth
Jounce Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Jounce Therapeutics has received a 75.46% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Jounce Therapeutics is -0.67.

3.6

News and Social Media Coverage

News Sentiment
Jounce Therapeutics has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Jounce Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for JNCE on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
3 people have added Jounce Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Jounce Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.92% of the stock of Jounce Therapeutics is held by insiders.
Percentage Held by Institutions
86.99% of the stock of Jounce Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Jounce Therapeutics are expected to decrease in the coming year, from ($2.29) to ($2.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Jounce Therapeutics is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Jounce Therapeutics is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Jounce Therapeutics has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Jounce Therapeutics (NASDAQ:JNCE) Stock

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JNCE Stock News Headlines

September 28, 2022 | americanbankingnews.com

Reviewing CRISPR Therapeutics (NASDAQ:CRSP) and Jounce Therapeutics (NASDAQ:JNCE)

September 7, 2022 | finance.yahoo.com

Jounce Therapeutics to Participate in the Upcoming Investor Conferences

August 31, 2022 | nasdaq.com

Jounce (JNCE) SELECT Study Fails to Meet Goal, Stock Down

August 30, 2022 | finance.yahoo.com

Jounce Therapeutics Shares Fall After Disappointing Mid-Stage Lung Cancer Trial Data

August 30, 2022 | marketwatch.com

Jounce Therapeutics Trial Fails to Meet Primary Endpoint

August 30, 2022 | markets.businessinsider.com

Jounce Therapeutics: SELECT Trial Of Vopratelimab Fails To Meet Primary Endpoint

August 30, 2022 | seekingalpha.com

Jounce drops ~29% as lung cancer therapy fails in mid-stage trial

August 30, 2022 | finance.yahoo.com

Jounce Therapeutics Reports Results from Phase 2 Randomized SELECT Trial Testing 2 Different Doses of Vopratelimab in TISvopra Biomarker-Selected Patients

August 5, 2022 | seekingalpha.com

Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q2 2022 Results - Earnings Call Transcript

August 4, 2022 | finance.yahoo.com

Jounce Therapeutics Reports Second Quarter 2022 Financial Results

July 30, 2022 | morningstar.com

Jounce Therapeutics Inc Stock Quote JNCE

July 28, 2022 | finance.yahoo.com

Jounce Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022

July 13, 2022 | finance.yahoo.com

We're Keeping An Eye On Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Rate

May 23, 2022 | markets.businessinsider.com

4 Analysts Have This to Say About Jounce Therapeutics

May 17, 2022 | finance.yahoo.com

Jounce Therapeutics to Present at Upcoming Investor Conferences

May 14, 2022 | finance.yahoo.com

Analysts Are More Bearish On Jounce Therapeutics, Inc. (NASDAQ:JNCE) Than They Used To Be

May 11, 2022 | seekingalpha.com

Jounce Therapeutics slides after Baird pulls bullish view on JTX-8064 concerns

May 10, 2022 | finance.yahoo.com

Jounce Therapeutics (NASDAQ:JNCE) shareholders have endured a 80% loss from investing in the stock five years ago

May 7, 2022 | seekingalpha.com

Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q1 2022 Results - Earnings Call Transcript

May 6, 2022 | seekingalpha.com

Jounce upgraded to Strong Buy at Raymond James after pipeline updates

May 6, 2022 | seekingalpha.com

Jounce Therapeutics Q1 2022 Earnings Preview

May 5, 2022 | finance.yahoo.com

Jounce Therapeutics Reports First Quarter 2022 Financial Results

April 29, 2022 | theglobeandmail.com

Instrument Name Jounce Therapeutics Inc Instrument Symbol (JNCE-Q)

April 28, 2022 | finance.yahoo.com

Jounce Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022

April 4, 2022 | nasdaq.com

Jounce Therapeutics, Inc. Common Stock (JNCE)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JNCE Company Calendar

Last Earnings: 8/04/2022
Today: 9/29/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:JNCE
CUSIP: N/A
CIK: 1640455
Web: www.jouncetx.com
Phone: (857) 259-3840
Fax: N/A
Employees: 137
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.00
High Stock Price Forecast: $17.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +400.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-90,870,000.00
Net Margins: N/A
Pretax Margin: -400.86%
Return on Equity: -63.86%
Return on Assets: -56.03%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.78
Quick Ratio: 6.78

Sales & Book Value

Annual Sales: $26.91 million
Price / Sales: 4.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.37 per share
Price / Book: 0.50

Miscellaneous

Outstanding Shares: 51,694,000
Free Float: 48,117,000
Market Cap: $113.73 million
Optionable: Optionable
Beta: 1.10

Key Executives

Dr. Richard Murray Ph.D. (Age 63)
Pres, CEO & Director
Comp: $887.4k

Mr. Hugh M. Cole (Age 57)
Chief Operating Officer
Comp: $607.44k

Dr. Elizabeth G. Trehu M.D. (Age 62)
Chief Medical Officer
Comp: $639.6k

Dr. James Patrick Allison Ph.D.
Founder

Dr. Thomas F. Gajewski M.D.
Ph.D., Founder

Dr. Robert D. Schreiber Ph.D.
Founder

Dr. Drew Mark Pardoll M.D.
Ph.D., Founder

Dr. Padmanee Sharma M.D.
Ph.D., Founder

Dr. Louis M. Weiner M.D. (Age 70)
Founder

Ms. Kimberlee Cobleigh Drapkin CPA (Age 54)
CPA, CFO & Treasurer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

JNCE Stock - Frequently Asked Questions

Should I buy or sell Jounce Therapeutics stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" JNCE shares.
View JNCE analyst ratings or view top-rated stocks.
What is Jounce Therapeutics' stock price forecast for 2022?: 7 brokerages have issued 12-month price objectives for Jounce Therapeutics' shares. Their JNCE share price forecasts range from $5.00 to $17.00. On average, they predict the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 402.3% from the stock's current price.
View analysts price targets for JNCE or view top-rated stocks among Wall Street analysts.
How have JNCE shares performed in 2022?: Jounce Therapeutics' stock was trading at $8.35 on January 1st, 2022. Since then, JNCE shares have decreased by 73.8% and is now trading at $2.19.
View the best growth stocks for 2022 here.
When is Jounce Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our JNCE earnings forecast.
How were Jounce Therapeutics' earnings last quarter?: Jounce Therapeutics, Inc. (NASDAQ:JNCE) announced its quarterly earnings data on Thursday, August, 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.03.
What is Richard Murray Ph.D's approval rating as Jounce Therapeutics' CEO?: 45 employees have rated Jounce Therapeutics Chief Executive Officer Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among the company's employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jounce Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), CRISPR Therapeutics (CRSP), Novavax (NVAX), Mylan (MYL), Progenics Pharmaceuticals (PGNX), Adaptimmune Therapeutics (ADAP), Incyte (INCY) and Nektar Therapeutics (NKTR).
When did Jounce Therapeutics IPO?: (JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.
What is Jounce Therapeutics' stock symbol?: Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."
How do I buy shares of Jounce Therapeutics?: Shares of JNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Jounce Therapeutics' stock price today?: One share of JNCE stock can currently be purchased for approximately $2.19.
How much money does Jounce Therapeutics make?: Jounce Therapeutics (NASDAQ:JNCE) has a market capitalization of $113.20 million and generates $26.91 million in revenue each year. The company earns $-90,870,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.
How many employees does Jounce Therapeutics have?: The company employs 137 workers across the globe.
How can I contact Jounce Therapeutics?: Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.jouncetx.com. The company can be reached via phone at (857) 259-3840 or via email at mdeon@jouncetx.com.

This page (NASDAQ:JNCE) was last updated on 9/29/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Jounce Therapeutics - JNCE Stock Forecast, Price & News

Jounce Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows